Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM

doi:10.1093/ejhf/xuag048

Heart failure & cardiomyopathies

Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM

Eur J Heart FailPublished 20 Feb 2026Post-hoc analysis of the ATTRibute-CM randomised trial

Primary result · CMI in NT-proBNP or 6MWDResultOdds ratio 3.0 95% CI 1.8–5.1

Read the original article ↗

Cite

Authors' conclusion

Acoramidis led to CMI from baseline in NT-proBNP concentration or 6MWD in a considerable proportion of participants with ATTR-CM.

Study context

Population: Participants with ATTR-CM in the phase 3 ATTRibute-CM trialanalysed
Participants: 611 participants

Comparison: Acoramidis vs placebo
Acoramidisn = 409
Placebon = 202reference
Primary endpoint: Clinically meaningful improvement (CMI) in NT-proBNP (decrease >700 ng/L and >30%) or 6MWD (increase >35 m)
Follow-up: Month 30

Methodological detailsphase 3

Phase 3

Primary result

CMI in NT-proBNP or 6MWD

Odds ratio

3.0

95% CI 1.8–5.1

P < 0.001

By group

Acoramidis22.7%

Placebo8.9%

Acoramidis vs Placebo

OR 3.0 (95% CI 1.8–5.1); P < 0.001

As reported in the abstract

Original publication

Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM. Eur J Heart Fail. Published 20 February 2026. doi:10.1093/ejhf/xuag048

Read the original article ↗PubMed

Summarised from the published abstract; every number is checked against it